Clinical significance of recipient antibodies to stem cell donor mismatched class I HLA antigens

Marilyn S. Pollack, David Ririe

Resultado de la investigación: Articlerevisión exhaustiva

13 Citas (Scopus)


A stem cell transplant candidate whose best-matched related donor had a mismatch for A68 by virtue of the patient's maternal human leukocyte antigen A/ B (HLA-A/B) recombinant haplotype, was referred to Wilford Hall Medical Center for transplantation. She was determined prior to transplant to have a high-titered antibody to that HLA type and to several crossreactive antigens (A2 and A24). When she initially failed to engraft, plasmapheresis was tried three times with no effect on the antibody titer. Subsequently, plasmapheresis followed by intravenous immunoglobulin treatment and retransplant completely eliminated the donor-specific antibody. Engraftment occurred, and several weeks after the second transplant antibodies to A68 could no longer be detected although the antibodies to other HLA types were still present. This case report should serve to remind stem cell transplant programs of the importance of checking for the presence of recipient antibodies to donor-mismatched antigens and suggests that patients with such antibodies be treated prior to transplant.

Idioma originalEnglish (US)
Páginas (desde-hasta)245-247
Número de páginas3
PublicaciónHuman Immunology
EstadoPublished - mar 2004

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Profundice en los temas de investigación de 'Clinical significance of recipient antibodies to stem cell donor mismatched class I HLA antigens'. En conjunto forman una huella única.

Citar esto